Roth/MKM Resumes aTyr Pharma (LIFE) at Buy, PT $9, 'Efzofitimod Has Potential in Fibrotic Lung Diseases'
Tweet Send to a Friend
(Updated - March 3, 2023 8:05 AM EST)
Roth/MKM analyst Kumaraguru Raja resumes coverage on aTyr Pharma (NASDAQ: LIFE) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Roth/MKM analyst Kumaraguru Raja resumes coverage on aTyr Pharma (NASDAQ: LIFE) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
